drugset / Trial / NCT07023835
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Timeline
- Start
- 2025-09-17
- Primary completion
- 2028-03
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Usnoflast | Small molecule | 50 mg | Oral |
| Comparator | Usnoflast | Small molecule | 75 mg | Oral |